Skip to main content

Gordon Carl L's Form 4 filing

BlossomHill Therapeutics, Inc. (BLSM) · filed Aug 12, 2026

Accession no.
0000947871-26-000785
Filed
Aug 12, 2026, 4:46 PM ET
Trade date
Aug 10, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $10.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gordon Carl LCIK 0001282930Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 10, 2026Common StockCConversionAcquired+1,039,996–F1–1,039,996IndirectDuplicate filing
Aug 10, 2026Common StockCConversionAcquired+1,049,283–F1–2,089,279IndirectDuplicate filing
Aug 10, 2026Common StockPPurchaseAcquired+625,000$16.00+$10,000,0002,714,279IndirectDuplicate filing

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 10, 2026Common StockCConversionDisposed−1,039,996$0.00$00IndirectDuplicate filing
Aug 10, 2026Common StockCConversionDisposed−1,049,283$0.00$00IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)